Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 79.85 EUR -1.11% Market Closed
Market Cap: 1.4B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Intrinsic Value

The intrinsic value of one PHM stock under the Base Case scenario is 33.67 EUR. Compared to the current market price of 79.85 EUR, Pharma Mar SA is Overvalued by 58%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHM Intrinsic Value
33.67 EUR
Overvaluation 58%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pharma Mar SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PHM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PHM?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Pharma Mar SA

Provide an overview of the primary business activities
of Pharma Mar SA.

What unique competitive advantages
does Pharma Mar SA hold over its rivals?

What risks and challenges
does Pharma Mar SA face in the near future?

Summarize the latest earnings call
of Pharma Mar SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharma Mar SA.

Provide P/S
for Pharma Mar SA.

Provide P/E
for Pharma Mar SA.

Provide P/OCF
for Pharma Mar SA.

Provide P/FCFE
for Pharma Mar SA.

Provide P/B
for Pharma Mar SA.

Provide EV/S
for Pharma Mar SA.

Provide EV/GP
for Pharma Mar SA.

Provide EV/EBITDA
for Pharma Mar SA.

Provide EV/EBIT
for Pharma Mar SA.

Provide EV/OCF
for Pharma Mar SA.

Provide EV/FCFF
for Pharma Mar SA.

Provide EV/IC
for Pharma Mar SA.

Show me price targets
for Pharma Mar SA made by professional analysts.

What are the Revenue projections
for Pharma Mar SA?

How accurate were the past Revenue estimates
for Pharma Mar SA?

What are the Net Income projections
for Pharma Mar SA?

How accurate were the past Net Income estimates
for Pharma Mar SA?

What are the EPS projections
for Pharma Mar SA?

How accurate were the past EPS estimates
for Pharma Mar SA?

What are the EBIT projections
for Pharma Mar SA?

How accurate were the past EBIT estimates
for Pharma Mar SA?

Compare the revenue forecasts
for Pharma Mar SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharma Mar SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharma Mar SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharma Mar SA compared to its peers.

Compare the P/E ratios
of Pharma Mar SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharma Mar SA with its peers.

Analyze the financial leverage
of Pharma Mar SA compared to its main competitors.

Show all profitability ratios
for Pharma Mar SA.

Provide ROE
for Pharma Mar SA.

Provide ROA
for Pharma Mar SA.

Provide ROIC
for Pharma Mar SA.

Provide ROCE
for Pharma Mar SA.

Provide Gross Margin
for Pharma Mar SA.

Provide Operating Margin
for Pharma Mar SA.

Provide Net Margin
for Pharma Mar SA.

Provide FCF Margin
for Pharma Mar SA.

Show all solvency ratios
for Pharma Mar SA.

Provide D/E Ratio
for Pharma Mar SA.

Provide D/A Ratio
for Pharma Mar SA.

Provide Interest Coverage Ratio
for Pharma Mar SA.

Provide Altman Z-Score Ratio
for Pharma Mar SA.

Provide Quick Ratio
for Pharma Mar SA.

Provide Current Ratio
for Pharma Mar SA.

Provide Cash Ratio
for Pharma Mar SA.

What is the historical Revenue growth
over the last 5 years for Pharma Mar SA?

What is the historical Net Income growth
over the last 5 years for Pharma Mar SA?

What is the current Free Cash Flow
of Pharma Mar SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharma Mar SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharma Mar SA

Current Assets 224.1m
Cash & Short-Term Investments 135.1m
Receivables 30m
Other Current Assets 59m
Non-Current Assets 93m
Long-Term Investments 5.3m
PP&E 54.7m
Intangibles 1.4m
Other Non-Current Assets 31.5m
Current Liabilities 87.9m
Accounts Payable 32.8m
Accrued Liabilities 1.1m
Short-Term Debt 4.9m
Other Current Liabilities 49.2m
Non-Current Liabilities 47.8m
Long-Term Debt 27.4m
Other Non-Current Liabilities 20.4m
Efficiency

Earnings Waterfall
Pharma Mar SA

Revenue
158.8m EUR
Cost of Revenue
-10.5m EUR
Gross Profit
148.3m EUR
Operating Expenses
-158.2m EUR
Operating Income
-9.8m EUR
Other Expenses
8.1m EUR
Net Income
-1.8m EUR

Free Cash Flow Analysis
Pharma Mar SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company's financial highlights for the year include increased investment in Research & Development (R&D) and a rise in royalties from ZEPZELCA in the U.S. Despite facing challenges such as competition from generics affecting YONDELIS revenue in Europe, the company's balance sheet remains strong. They are advancing clinical trials and anticipate these strategies to produce positive developments. In the coming year, they expect results from several trials: Phase II of lurbi and IO, completion of LAGOON trial recruitment, and data release for Phase II of lurbi and azo. They also predict top-line PFS data from the IMforte trial and Phase III results of tivanisiran.

What is Earnings Call?
Fundamental Scores

PHM Profitability Score
Profitability Due Diligence

Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Exceptional 3-Year Average ROE
Negative Net Income
58/100
Profitability
Score

Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

PHM Solvency Score
Solvency Due Diligence

Pharma Mar SA's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
High Altman Z-Score
Short-Term Solvency
61/100
Solvency
Score

Pharma Mar SA's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHM Price Targets Summary
Pharma Mar SA

Wall Street analysts forecast PHM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHM is 68.14 EUR with a low forecast of 29.9 EUR and a high forecast of 107.1 EUR.

Lowest
Price Target
29.9 EUR
63% Downside
Average
Price Target
68.14 EUR
15% Downside
Highest
Price Target
107.1 EUR
34% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PHM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PHM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Pharma Mar SA Logo
Pharma Mar SA

Country

Spain

Industry

Biotechnology

Market Cap

1.4B EUR

Dividend Yield

0.81%

Description

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

Contact

MADRID
Colmenar Viejo
Avda. De los Reyes, 1, Pol. Ind. La Mina
+34918466000.0
www.pharmamar.com

IPO

2015-11-02

Employees

477

Officers

Founder, Executive Chairman, CEO & President
Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
Executive Vice-Chairman
Mr. Pedro Francisco Fernandez Puentes
Founder
Mr. Juan Carlos-Torres Carretero
Chief Financial Officer
Ms. MarĂ­a Luisa de Francia Caballero
Head of Capital Markets & Investor Relations
Mr. José Luis Moreno Martinez-Losa
General Counsel & Secretary of the Board of Directors
Mr. Juan Gomez Pulido
Show More
Global Compliance Head
Ms. Sandra Llamera Sanchez
Communication Director
Ms. Lara Vadillo
Director of Corporate Development
Ms. Belén Sopesén Veramendi Ph.D.
Director of Human Resources & IT
Mr. Luis Rupérez Cuenca
Show Less

See Also

Discover More
What is the Intrinsic Value of one PHM stock?

The intrinsic value of one PHM stock under the Base Case scenario is 33.67 EUR.

Is PHM stock undervalued or overvalued?

Compared to the current market price of 79.85 EUR, Pharma Mar SA is Overvalued by 58%.

Back to Top